Pharma's Almanac TV
PA TV
Your Name
Your Email
Manage Account
Sign Out
Sign In
Register
Follow the Journey
Companies On The Road
Arcadis DPS Group
C2 Pharma
CAI
EcoLab
Environmental Systems Corporation
Federal Equipment Company
Globyz Biopharma Services
Grifols
Integrity
Nu-Tek BioSciences
PHARMALEX
Waters Corporation
Follow the Journey
Companies On The Road
ABS
aCGT Vector
Alconox Inc.
Andelyn Biosciences
Arranta Bio
Avid Bioservices
BDD
BIOVECTRA
DPS Group
Dynamk Capital
Environmental Systems Corporation
Federal Equipment Company
Genesis AEC
Globyz Biopharma Services
Grifols Partnership
IDT Biologika
Inceptor Bio
IPS-Integrated Project Services
Kineticos Life Sciences
MilliporeSigma
Montana BioScience Alliance
Olon
Rentschler Biopharma
SanaClis
Scorpion Biological Services
Secant Group
Tapemark
VITRONIC
Follow the Journey
Companies On The Road
AES Clean Technology
Altis Biosystems
Arranta Bio
Avara Pharmaceutical Services
Avid Bioservices
BioVectra
Centaur BPS
Dynamk Capital
ECRI
Evolve Biologics
Federal Equipment Company
Globyz
Inceptor Bio
IPS-Integrated Project Services
Olon
Pii
Polpharma Biologics
PPD
RoosterBio
SanaClis
Sanofi AIS
SGD Pharma
SPI Pharma
TriRx Pharmaceutical Services
Yourway
Dashboard
Topics
Products
ADC
API - Small Molecule
Biologics
Biopharmaceuticals
Biosimilars
Cell and Gene Therapy
DNA
Drug Product
Drug Substance
Equipment
Generics
Immunotherapy
Injectables
Monoclonal Antibody
Novel Therapeutics
Oral Solid Dosage
Orphan Drugs
Parenterals
Stem Cells
Vaccine
Services
Big Data
Bioprocessing
Clinical Trials
Continuous Manufacturing
Diagnostics
Drug Delivery
Drug Development
Drug Discovery
Facility
Formulation
Innovation
Oncology
Patient Adherence
Patient Centric
Preclinical
Process Development
Quality
Regulatory
Research
Serialization
Segment
Biomanufacturing
Biotechnology
CDMO
Consulting
CRO
Engineering
Equipment
Excipients
Healthcare
Intermediates
Logistics
Manufacturing
Packaging
Supply Chain
Business
Agreement
Appointment
Business
Capacity Expansion
Collaboration
Growth
Investment
Licensing
M&A
Market Expansion
Market Intelligence
Market Prediction
New Facility
Strategic Partnership
Magazine
Archive
Reports
Nice Insight Reports
2022 Sterile
2023 Cell & Gene Therapy
2023 mAb and Recombinant Protein
2024 API
2024 OSD
2024 ADC
2024 mRNA
2024 Mammalian Cell Culture
2024 Microbial Cell Culture
2024 Plasmids
2024 Gene Therapy
2024 Cell Therapy
2024 Sterile
Community
Company A to Z
Follow the Journey
Companies On The Road
Follow The Artist
Follow the Journey
Companies On The Road
More+
Staffing
Media Kit
Array BioPharma
15 Articles Available
Can't find what you're looking for? Try our
advanced search
.
M&A
Pfizer Completes Acquisition of Array Biopharma
PR-M07-19-NI-080
Clinical Results
Positive Results for Colon Cancer Drug Drove Pfizer’s Purchase of Array BioPharma
PAO-M07-19-NI-017
M&A
Pfizer Acquires Array BioPharma for $11.4 Billion
PAO-M06-19-NI-018
M&A
Pfizer to Acquire Array BioPharma
PR-M06-19-NI-027
Endpoint
Array Biopharma Announces Braftovi + Mektovi + Cetuximab Meet Primary Endpoints in Metastatic Colorectal Cancer
PR-M05-19-NI-069
Vaccines
GSK Ships 2018-19 Seasonal Influenza Vaccines for US Market
PR-M08-18-NI-110
FDA Designation
Array BioPharma Receives FDA Breakthrough Therapy Designation for BRAFTOVI™ in combination with MEKTOVI® and cetuximab for BRAFV600E-mutant Metastatic Colorectal Cancer
PR-M08-18-NI-070
Clinical Data
BRAFTOVI™ (encorafenib) + MEKTOVI® (binimetinib) Receives Positive CHMP Opinion for Advanced BRAF-mutant Melanoma
PR-M08-18-NI-010
Clinical Data
Array BioPharma Announces a 62% Observed Overall Survival at One Year from the Phase 3 BEACON CRC Safety Lead-In
PR-M06-18-NI-086
Clinical Trials
Array BioPharma to Present Overall Survival Results from the Phase 3 LUNGevity Takes Step Forward in Clinical Trial Eligibility Reform for Lung Cancer Patients
PR-M06-18-NI-062
Clinical Data
Pierre Fabre and Array BioPharma Announce COLUMBUS Phase 3 Study Overall Survival Results in BRAF-Mutant Melanoma Will Be Presented at 2018 ASCO Annual Meeting
PR-M05-18-NI-076
Clinical Trials
Encorafenib and Binimetinib Combination Treatment Demonstrates 33.6 Month Median Overall Survival (OS) in Patients with BRAF-Mutant Melanoma
PR-M02-18-NI-043
Oncology
Combination of Encorafenib, Binimetinib and Cetuximab Demonstrated an 8 Month Median Progression-Free Survival
PR-M01-18-NI-081
Drug Development
Array BioPharma Forms New Subsidiary Yarra Therapeutics
PAO-M01-18-NI-007
Immuno-Oncology
Bristol-Meyers Squibb, Array BioPharma Enter Strategic Collaboration
PAO-M05-17-NI-036
.svg)
